In vivo priming of human mesenchymal stem cells with hepatocyte growth factor–engineered mesenchymal stem cells promotes therapeutic potential for cardiac repair
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Priming human BM-MSCs with engineered HGF-MSCs in vivo significantly improves therapeutic potential for myocardial infarction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Fig. 5 Survival of in vivo primed BM-MSC in MI hearts and their effects on vascular regeneration and cardioprotection. (A to C) Survival of hMSCs and HGF-eMSC within the cardiac patch after 8 weeks from implantation into the MI-induced rat hearts and their quantification summary. (A) Representative images of hMSCs [DiI (1.1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocynanine perchlorate), red], HGF-eMSC [DiO (3,3ʹ-Dioctadecyloxacarbocyanine perchlorate), green], TUNEL signal (gray), and 4′,6-diamidino-2-phenylindole (DAPI) for nucleus (blue) within the patch made by using hdECM. (B) Number of either DiI- or DiO-positive MSCs. (C) Number of TUNEL signal–positive MSCs. Scale bars, 50 μm. n = 5 per group. (D) Representative images of capillaries stained with fluorescein isothiocyanate (FITC)–IB4 (green) on the infarct zone (IZ), border zone (BZ), and remote zone at 8 weeks after MI and (E to G) their quantification summary in three areas. For quantification, the number of capillaries on five randomly selected fields in each heart was counted. Scale bars, 50 μm. *P < 0.05 compared to control group; †P < 0.05 compared to BM-MSC group; ‡P < 0.05 compared to HGF-eMSC group. n = 5 per group. (H) Representative immunostaining images with cardiac-specific TNNT2 (red), TUNEL signal (gray), and DAPI for nucleus (blue) at 8 weeks after MI and (I and J) their quantification summary. Scale bars, 50 μm. *P < 0.05 compared to control group; †P < 0.05 compared to BM-MSC group; ‡P < 0.05 compared to HGF-eMSC group. n = 5 to 9 for each group.](https://figures.cochat.ai/paper-figures/f4f928772ad34abe81b3917922f7543b/in-vivo-priming-of-human-mesenchymal-stem-cells-with-hepatocyte-growth-figure-5.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Such a combination of synthetic structural materials (such as PCL and poly-(lactic-co-glycolic acid)) with natural materials (such as fibrin and collagen) might be a prevalent trend in engineering cardiac tissues, whose functionality is highly related to the ECM microenvironment and mechanical property 3,63,64 .”
From Leaf-venation-directed cellular alignment for macroscale cardiac constructs with tissue-like functionalities (2023) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
Printing three-dimensional tissue analogues with decellularized extracellular matrix bioink
Pati, F., Jang, J., Ha, D.-H., Won Kim, S., Rhie, J.-W., Shim, J.-H., Kim, D.-H., & Cho, D.-W. (2014) · Nature Communications · doi:10.1038/ncomms4935 · Cited by 1,904
Self-citationGnecchi, M., He, H., Liang, O. D., Melo, L. G., Morello, F., Mu, H., Noiseux, N., Zhang, L., Pratt, R. E., Ingwall, J. S., et al. (2005) · Nature Medicine · doi:10.1038/nm0405-367 · Cited by 1,677
Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies
Noronha, N. D. C., Mizukami, A., Caliári-Oliveira, C., Cominal, J. G., Rocha, J. L. M., Covas, D. T., Swiech, K., & Malmegrim, K. C. R. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1224-y · Cited by 623 · cited 2×
“…studies of the underlying mechanisms of the priming effects reported that hMSCs receiving these priming applications had short-term memory and remembered a priming stimulus, even after relocating to new environments, and shifted their phenotype in therapeutically desirable directions ( 14 , 16 ).”
Bcl-2 Engineered MSCs Inhibited Apoptosis and Improved Heart Function
Li, W., Ma, N., Ong, L.-L., Nesselmann, C., Klopsch, C., Ladilov, Y., Furlani, D., Piechaczek, C., Moebius, J. M., Lützow, K., et al. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0771 · Cited by 440
Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF
Nakamura, T., Mizuno, S., Matsumoto, K., Sawa, Y., Matsuda, H., & Nakamura, T. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10226 · Cited by 434
Haider, H. K., Jiang, S., Idris, N. M., & Ashraf, M. (2008) · Circulation Research · doi:10.1161/circresaha.108.186742 · Cited by 422
Manufacturing of primed mesenchymal stromal cells for therapy
Yin, J. Q., Zhu, J., & Ankrum, J. A. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0325-8 · Cited by 343
Mechanism of Cardioprotection by Early Ischemic Preconditioning
Yang, X., Cohen, M. V., & Downey, J. M. (2010) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-010-6236-x · Cited by 200
Singh, A., Singh, A., & Sen, D. (2016) · Stem Cell Research & Therapy · doi:10.1186/s13287-016-0341-0 · Cited by 192
Yang, J., Zhou, W., Zheng, W., Ma, Y., Lin, L., Tang, T., Liu, J., Yu, J., Zhou, X., & Hu, J. (2006) · Cardiology · doi:10.1159/000093609 · Cited by 139
A potential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats
Ueda, H. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00272-3 · Cited by 132
Mesenchymal stem cells and cardiac repair
Neßelmann, C., Ma, N., Bieback, K., Wagner, W., Ho, A. D., Konttinen, Y. T., Zhang, H., Hinescu, M. E., & Steinhoff, G. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00457.x · Cited by 122
Hepatocyte growth factor protects cardiac myocytes against oxidative stress-induced apoptosis
Kitta, K., Day, R. M., Ikeda, T., & Suzuki, Y. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00663-3 · Cited by 101
Sonnenberg, S. B., Rane, A. A., Liu, C. J., Rao, N., Roth, G. A., Suarez, S. L., Wang, R. M., Muñoz, A., Bajaj, V., Zhang, S. X., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.12.021 · Cited by 100
Mesenchymal Stem Cells for Cardiac Therapy: Practical Challenges and Potential Mechanisms
Cashman, T. J., Gouon–Evans, V., & Costa, K. D. (2012) · Stem Cell Reviews and Reports · doi:10.1007/s12015-012-9375-6 · Cited by 97
Qiu, Y., Tang, X., Park, S.-W., Sun, J.-Z., Kalya, A. V., & Bolli, R. (1997) · Circulation Research · doi:10.1161/01.res.80.5.730 · Cited by 87
Ji, S. T., Kim, H., Yun, J., Chung, J. S., & Kwon, S. (2017) · Stem Cells International · doi:10.1155/2017/3945403 · Cited by 78
Self-citationMesenchymal Stem Cells in Cardiology
White, I. A., Sanina, C., Balkan, W., & Hare, J. M. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3584-0_4 · Cited by 71
Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?
Roura, S., Gálvez‐Montón, C., Mirabel, C., Vives, J., & Bayés‐Genís, A. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0695-y · Cited by 53
Priming mesenchymal stem cells boosts stem cell therapy to treat myocardial infarction
Carvalho, J. L., Braga, V. B. A., Melo, M. B., Campos, A. C. D. A., Barreto, M. S. O., Gomes, D. A., Ferreira, A. J., Santos, R. A. S., & Goes, A. M. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12036 · Cited by 50
Zhang, Y., Li, R., Rong, W., Han, M., Cui, C., Feng, Z., Sun, X., & Jin, S. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-1239-9 · Cited by 47
Priming of the Cells: Hypoxic Preconditioning for Stem Cell Therapy.
Wei, Z. Z., Zhu, Y., Zhang, J. Y., McCrary, M. R., Wang, S., Zhang, Y., Yu, S., & Wei, L. (2017) · PubMed Central · doi:10.4103/0366-6999.215324 · Cited by 43
Signaling Mechanisms in Ischemic Preconditioning
Ardehali, H. (2006) · Circulation Research · doi:10.1161/01.res.0000247029.31997.a4 · Cited by 26
HGF Gene Therapy for Therapeutic Angiogenesis in Peripheral Artery Disease
Muratsu, J., Sanada, F., Taniyama, Y., Ikeda-Iwabu, Y., Otsu, R., Shibata, K., Brulé, M. K., Rakugi, H., & Morishita, R. (2017) · Springer eBooks · doi:10.1007/978-981-10-2744-4_9 · Cited by 4
Cited by
Effects of Mesenchymal Stem Cell‐Derived Paracrine Signals and Their Delivery Strategies
Chang, C., Yan, J., Yao, Z., Zhang, C., Li, X., & Mao, H. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001689 · Cited by 248
Hybrid assembly of polymeric nanofiber network for robust and electronically conductive hydrogels
He, H., Li, H., Pu, A., Li, W., Ban, K., & Xu, L. (2023) · Nature Communications · doi:10.1038/s41467-023-36438-8 · Cited by 236
Self-citationMesenchymal stem cell-derived exosome: a promising alternative in the therapy of Alzheimer’s disease
Guo, M., Yin, Z., Chen, F., & Lei, P. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00670-x · Cited by 200
Advanced Cardiac Patches for the Treatment of Myocardial Infarction
Liu, T., Hao, Y., Zhang, Z., Zhou, H., Peng, S., Zhang, D., Li, K., Chen, Y., & Chen, M. (2024) · Circulation · doi:10.1161/circulationaha.123.067097 · Cited by 196
3D bioprinting in cardiac tissue engineering
Wang, Z., Wang, L., Li, T., Liu, S., Guo, B., Huang, W., & Wu, Y. (2021) · Theranostics · doi:10.7150/thno.61621 · Cited by 185
Metadata
- Authors
- Park, B.-W., Jung, S.-H., Das, S., Lee, S. M., Park, J.-H., Kim, H., Hwang, J.-W., Lee, S., Kim, H.-J., Kim, H.-Y., Jung, S., Cho, D.-W., Jang, J., Ban, K., & Park, H.-J.
- Affiliations
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Pohang University of Science and Technology (KR)
- City University of Hong Kong (HK)
- Department of Biomedical Sciences, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong SAR.
- Corresponding author
- Jang, Jinah
- Ban, Kiwon
- Park, Hun-Jun
- ORCID
- Venue
- Science Advances
- Published
- 2020-03-27
- Volume
- 6
- Issue
- 13
- Pages
- eaay6994-eaay6994
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC7141892
- OpenAlex
- W3013134172
- Cited by
- 133
- References
- 25
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 24 · 2023: 19 · 2022: 30 · 2021: 23 · 2020: 7
- FWCI
- 10.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- CityU Scholars (submittedVersion, cc-by-nc)
- Funders
- National Research Foundation of Korea grants (2016R1C1B2015529)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- mesenchymal stem cells, bone marrow-derived stem cells, hepatocyte growth factor, in vivo priming, myocardial infarction, cardiac repair, epicardial implantation, vasculogenesis, vascular regeneration, cardiomyocyte survival, cardioprotection, cell transplantation
- MeSH terms
- Animals, Disease Models, Animal, Genetic Engineering, Heart Diseases, Humans, Myocardial Infarction, Swine, Gene Expression, Hepatocyte Growth Factor, Cell Culture Techniques, Myocytes, Cardiac, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.